Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major technology-transfer agreement with Eli Lilly.
Search results for "treatment"
Life-Saving Heart Surgeries Give Four Kyrgyz Children a Fresh Start in South Korea
A seven-month-old infant who faced a life-threatening crisis without urgent intervention by the end of the year has successfully recovered following...
Depressive Symptoms Linked to Higher Fatty Liver Risk in Young Adults
Young adults in South Korea who experience depressive symptoms face roughly twice the risk of developing fatty liver...
Asan Medical Center Performs South Korea’s First Artisse Implant to Seal Complex Brain Aneurysms
Treating a brain aneurysm presents steep clinical challenges when the lesion features a wide neck or develops at a...
'A Hellish Time': Chronic Ear Disorder Forces IU to Postpone Concert Tour and Album Release
Singer and actor IU, 33, has postponed her upcoming September concert tour and the release of her sixth full-length...
Too Much Air Conditioning? How Summer Cooling Drives Dry Eyes and Eczema
Sweltering heat, frequent rain, and suffocating humidity have pushed the discomfort index to high levels in recent days.
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
Blood Sugar Control After Stomach Cancer Surgery Varies Sharply by Intestinal Reconstruction Method
For patients navigating both stomach cancer and type 2 diabetes, the surgical method used to reconnect the digestive...
Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.